KRAS-Mutant Pancreatic Cancer Medication Savings with TheDrugClub
Discount pricing may be available. Current formulary eligibility is being verified; a condition association does not establish FREE coverage.
- Join TheDrugClub as a member
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
About KRAS-Mutant Pancreatic Cancer
Pancreatic cancer is one of the most challenging cancers to treat, and a significant portion of cases, around 90%, are driven by mutations in the KRAS gene. This "KRAS mutant" form of pancreatic cancer is particularly aggressive, often diagnosed at advanced stages, and known for its resistance to conventional therapies. The KRAS gene acts like a switch that, when mutated, gets stuck in the "on" position, continuously signaling cancer cells to grow and divide unchecked. This makes it a prime target for researchers developing new treatments, though historically, targeting KRAS directly has proven difficult. Understanding this genetic driver is crucial for personalizing treatment
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.